The Cytokine Release Syndrome Market represents a strategically significant domain within modern biopharmaceuticals, fundamentally shaped by revolutionary advances in immune-based and cellular oncology treatments. CRS constitutes a systemic inflammatory cascade potentially triggered by particular cancer therapeutics, most notably CAR-T cell platforms and monoclonal antibody...